company background image
HROW

Harrow Health NasdaqGM:HROW Stock Report

Last Price

US$17.50

Market Cap

US$521.3m

7D

18.8%

1Y

124.4%

Updated

05 Feb, 2023

Data

Company Financials +

HROW Stock Overview

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company.

HROW fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

New

Notes are coming soon

Harrow Health, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Harrow Health
Historical stock prices
Current Share PriceUS$17.50
52 Week HighUS$17.84
52 Week LowUS$5.40
Beta0.23
1 Month Change22.81%
3 Month Change50.60%
1 Year Change124.36%
3 Year Change153.62%
5 Year Change993.75%
Change since IPO102.34%

Recent News & Updates

Recent updates

Harrow sells non‑ophthalmic compounding business, terms undisclosed

Oct 05

Harrow Health soars ~27% on FDA nod of anesthesia gel for the surface of the eye

Sep 27

SRK Capital - Harrow Health: Market Missing The Forest For The Trees

Aug 19

These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively

Aug 11
These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively

Buy Deep Moated, Fast Growing, Superbly Managed Harrow Health Ahead Of New Product Launch

May 23

Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?

May 12
Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?

Is Harrow Health (NASDAQ:HROW) A Risky Investment?

Dec 15
Is Harrow Health (NASDAQ:HROW) A Risky Investment?

Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?

Aug 24
Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?

Harrow Health prices 8.625% senior notes due 2026

Jun 15

Harrow Health: An 8.3% Baby Bond Yield With Low Balance Sheet Leverage

May 28

Shareholders Shouldn’t Be Too Comfortable With Harrow Health's (NASDAQ:HROW) Strong Earnings

May 18
Shareholders Shouldn’t Be Too Comfortable With Harrow Health's (NASDAQ:HROW) Strong Earnings

Harrow Health, Inc. (NASDAQ:HROW) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 11
Harrow Health, Inc. (NASDAQ:HROW) Just Reported And Analysts Have Been Lifting Their Price Targets

Announcing: Harrow Health (NASDAQ:HROW) Stock Increased An Energizing 299% In The Last Three Years

Mar 08
Announcing: Harrow Health (NASDAQ:HROW) Stock Increased An Energizing 299% In The Last Three Years

Is Harrow Health (NASDAQ:HROW) Using Debt Sensibly?

Feb 01
Is Harrow Health (NASDAQ:HROW) Using Debt Sensibly?

How Is Harrow Health's (NASDAQ:HROW) CEO Compensated?

Dec 28
How Is Harrow Health's (NASDAQ:HROW) CEO Compensated?

Harrow Health: Eye Care On The Rise

Dec 07

Could The Harrow Health, Inc. (NASDAQ:HROW) Ownership Structure Tell Us Something Useful?

Dec 02
Could The Harrow Health, Inc. (NASDAQ:HROW) Ownership Structure Tell Us Something Useful?

Harrow Health EPS of $0.32

Nov 09

Shareholder Returns

HROWUS PharmaceuticalsUS Market
7D18.8%-0.5%1.7%
1Y124.4%4.6%-9.6%

Return vs Industry: HROW exceeded the US Pharmaceuticals industry which returned 4.6% over the past year.

Return vs Market: HROW exceeded the US Market which returned -9.6% over the past year.

Price Volatility

Is HROW's price volatile compared to industry and market?
HROW volatility
HROW Average Weekly Movement9.2%
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: HROW is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: HROW's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998182Mark Baumhttps://www.harrowinc.com

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.

Harrow Health, Inc. Fundamentals Summary

How do Harrow Health's earnings and revenue compare to its market cap?
HROW fundamental statistics
Market CapUS$521.33m
Earnings (TTM)-US$22.56m
Revenue (TTM)US$88.45m

5.9x

P/S Ratio

-23.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HROW income statement (TTM)
RevenueUS$88.45m
Cost of RevenueUS$24.30m
Gross ProfitUS$64.16m
Other ExpensesUS$86.72m
Earnings-US$22.56m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.76
Gross Margin72.53%
Net Profit Margin-25.50%
Debt/Equity Ratio8,380.4%

How did HROW perform over the long term?

See historical performance and comparison